Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.79 |
| ▸ | HPSE | Q9Y251 | 12/20 | 0.65 |
| ▸ | VDR | P11473 | 1/20 | 0.64 |
| ▸ | FGF1 | P05230 | 7/20 | 0.61 |
| ▸ | CDC25A | P30304 | 2/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | FGF2 | P09038 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11410558 | 1.00 | NR1H4 (0.79) | NR1H4HPSEVDRFGF1CDC25A | |
| SCHEMBL26642428 | 1.00 | NR1H4 (0.79) | NR1H4HPSEVDRFGF1CDC25A | |
| SCHEMBL30653065 | 1.00 | NR1H4 (0.79) | NR1H4HPSEVDRFGF1CDC25A | |
| SCHEMBL3391119 | 1.00 | NR1H4 (0.79) | NR1H4HPSEVDRFGF1CDC25A | |
| SCHEMBL15369124 | 0.94 | NR1H4 (0.70) | NR1H4HPSEFGF1FGF2 | |
| SCHEMBL2059166 | 0.89 | NR1H4 (0.68) | NR1H4HPSEFGF1CDC25APOLA1 | |
| SCHEMBL12590999 | 0.89 | NR1H4 (0.68) | NR1H4HPSEFGF1CDC25APOLA1 | |
| SCHEMBL13211407 | 0.89 | NR1H4 (0.68) | NR1H4HPSEFGF1CDC25APOLA1 | |
| SCHEMBL479186 | 0.89 | NR1H4 (1.00) | NR1H4VDR | |
| SCHEMBL31145546 | 0.89 | NR1H4 (0.77) | NR1H4HPSEVDRFGF1FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | NR1H4 122/4885HPSE 193/4885VDR 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.